Neuphoria Therapeutics Confirms Merger Talks With Scancell Holdings
Neuphoria Therapeutics has acknowledged active combination discussions with London-listed Scancell Holdings plc following a public announcement by the UK firm.
Neuphoria Therapeutics confirmed Thursday it is in active discussions with London-listed Scancell Holdings plc regarding a possible business combination, responding directly to a disclosure Scancell had already made public on the matter.
The confirmation places both companies formally on the record about deal talks that could reshape their respective positions in the oncology and immunotherapy space. Scancell, traded on the London Stock Exchange, initiated the public disclosure, prompting Neuphoria to issue its own statement acknowledging the negotiations.
Read more Universe Pharmaceuticals Buys Best Praise in $10.75M Deal →
No terms, valuation, or timeline for a potential deal have been disclosed by either party. Such combination discussions at this stage carry no guarantee that a transaction will ultimately be agreed upon, structured, or completed, and both companies face the customary regulatory and due-diligence hurdles that accompany cross-border merger activity.
The move signals potential consolidation within the biotech sector as smaller therapeutics firms increasingly explore strategic partnerships and mergers to accelerate clinical pipelines, pool resources, and strengthen their standing with investors on both sides of the Atlantic.
Continue reading at GlobalNewswire.
